Reovirus Agent Shows Activity in Phase I Trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 12
Volume 15
Issue 12

Results from Oncolytics Biotech's phase I trial of Reolysin, its oncolytic reovirus, show stable disease in 7 of 32 patients with advanced or metastatic solid tumors refractory to standard therapy or for which no curative standard therapy exists. Dr. Timothy Yap of The Institute of Cancer Research, Sutton, UK, presented the study at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

PRAGUE, Czech Republic—Results from Oncolytics Biotech's phase I trial of Reolysin, its oncolytic reovirus, show stable disease in 7 of 32 patients with advanced or metastatic solid tumors refractory to standard therapy or for which no curative standard therapy exists. Dr. Timothy Yap of The Institute of Cancer Research, Sutton, UK, presented the study at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (abstract 348).

Two patients with colorectal cancer had tumor stabilization lasting 3 months and 6 months, along with reductions in CEA of 27% and 60%, respectively, Dr. Yap said. One patient with metastatic prostate cancer had stable disease for 4 months, a 50% decrease in PSA, and extensive necrosis. A patient with metastatic bladder cancer had stable disease for 4 months and a minor response in a metastatic lymph node lesion (reduction from 2.5 to 1.9 cm). Patients with pancreatic cancer, non-small-cell lung cancer, and endometrial cancer also had stable disease lasting 4 to 5 months.

The agent has been well tolerated, Dr. Yap said, and the maximum tolerated dose has not been reached.

Recent Videos
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
4 experts in this video
4 experts in this video
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content